Regulatory & Legal

The firm expands its Target Outcome ETF suite with three new funds designed to manage timing risk and provide investors with defined downside protection.

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.

AEGIS Markets' record Q1 signals a seismic shift in commodity hedging, as firms ditch old methods for transparent, regulated digital platforms.

A new VC-backed program is giving elite female athletes the tailored health tools sports science has long ignored, aiming to optimize performance and longevity.

Tractive's new trackers for dogs and cats offer AI-powered health insights, moving beyond location to vitals. But how do they fare in a crowded market?

As AI-powered scams target private equity's billions, a new partnership combines accurate calculations with verified payments to lock fraudsters out for good.

As carriers retire old copper phone lines, MetTel's new solution wins Product of the Year for keeping critical services like fire alarms and E-911 online.

An Arizona mining project reports a major breakthrough in extracting gallium, a mineral vital for semiconductors and defense, potentially easing US reliance on China.

With a $137M war chest, Sidewinder Therapeutics is advancing a new class of ultra-precise cancer drugs aimed at tumors that have long evaded treatment.

Supira Medical gets FDA nod for a pivotal trial of its next-gen heart pump, adding an industry veteran to its board in a challenge to the status quo.

The women-only agency expands into tennis, adding Grand Slam champ Sloane Stephens and signaling a new model for athlete representation and ownership.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

Amid industry-wide financial strain, Kurin's simple device for preventing blood culture contamination delivers record growth by saving hospitals money and lives.

Tech giant HPE secures access to next-gen Wi-Fi 6 and 7 tech via Sisvel's patent pool, a move that validates collaborative IP and speeds innovation.

Hemispherian launches a landmark trial for GLIX1, a first-in-class therapy aiming to selectively destroy glioblastoma cells where others have failed.

A new alliance between Daiichi Sankyo and ATLATL aims to leverage a unique 'Super Server' model to fast-track novel therapies from Asia to the world.

A wound care gel recall by Blaine Labs reveals a history of contamination issues and prior FDA warnings, posing serious risks to vulnerable patients.

Otis College's 2026 report, featuring Snap CEO Evan Spiegel, will dissect AI's impact on California's creative jobs, innovation, and policy.

Facing credit defaults and a failed asset sale, the Western Canadian environmental services firm is now under court protection, seeking buyers for its business.

A new certification for AI-guided cardiac ultrasound seeks to solve the training and trust gap, making crucial heart scans more accessible for frontline providers.